Despite the global economic crisis, I believe certain life science sectors will remain resilient in Asia in 2009. Medical devices and pharmaceutical related sectors are in a way recession proof. The number of people requiring medical treatment and diagnostics continue to rise throughout Asia.
I see continued investment opportunities in China and India. These are such important large strategic markets in the region that will not be ignored by most companies, especially when healthcare demands remain high. For the few companies with the foresight and financial health to grow, 2009 is a great opportunity for them to gain market share rapidly in these markets. I know that there are medical device companies that are already planning to expand their presence in China and India by tapping into new “greenfield†segments in tier 2 and 3 cities through introduction of new cost effective products. Biotech may be the only weaker sector in life science as funding dries up. However, this also spells opportunity for large pharmaceutical companies with the money to buy small biotech companies with good product and concept at a bargain price. I believe we will see more strategic alliances and even acquisitions in the biotech sector.
Ivy Teh,
Managing Director, Clearstate
Comments are closed.